Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.

LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.

Neurology. 2008 May 27;70(22 Pt 2):2179-86. doi: 10.1212/01.wnl.0000313154.55518.25.

PMID:
18505997
2.
3.

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.

Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Crémieux PY.

Dis Manag. 2007 Aug;10(4):216-25.

PMID:
17718660
4.

Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.

Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, Harada AS, Curtis B.

Epilepsia. 2011 Jul;52(7):1365-71. doi: 10.1111/j.1528-1167.2011.03130.x. Epub 2011 Jun 21.

5.

The risks and costs of multiple-generic substitution of topiramate.

Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.

Neurology. 2009 Jun 16;72(24):2122-9. doi: 10.1212/WNL.0b013e3181aa5300.

PMID:
19528520
6.

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.

LeLorier J, Duh MS, Paradis PE, Latrémouille-Viau D, Lefebvre P, Manjunath R, Sheehy O.

Curr Med Res Opin. 2008 Apr;24(4):1069-81. doi: 10.1185/030079908X280572 . Epub 2008 Feb 29.

PMID:
18315941
7.

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.

Paradis PE, Latrémouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

Curr Med Res Opin. 2009 Jul;25(7):1793-805. doi: 10.1185/03007990903044374.

PMID:
19505202
9.

Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Hartung DM, Middleton L, Svoboda L, McGregor JC.

CNS Drugs. 2012 Aug 1;26(8):707-16. doi: 10.2165/11634260-000000000-00000.

10.

Economic burden associated with the use of generic antiepileptic drugs in the United States.

Helmers SL, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Labiner DM.

Epilepsy Behav. 2010 Aug;18(4):437-44. doi: 10.1016/j.yebeh.2010.05.015. Epub 2010 Jun 30.

PMID:
20580619
11.

The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.

Lessing C, Ashton T, Davis P.

Appl Health Econ Health Policy. 2014 Oct;12(5):537-46. doi: 10.1007/s40258-014-0110-0.

PMID:
25005492
12.

Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.

Kwong WJ, Kamat S, Fang C.

Ann Pharmacother. 2012 Dec;46(12):1609-16. doi: 10.1345/aph.1Q472. Epub 2012 Nov 13.

PMID:
23150608
13.

Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands.

Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, Hekster YA.

J Clin Pharm Ther. 2004 Apr;29(2):131-8.

PMID:
15068401
14.

Generic and therapeutic statin switches and disruptions in therapy.

Chapman RH, Benner JS, Girase P, Benigno M, Axelsen K, Liu LZ, Nichol MB.

Curr Med Res Opin. 2009 May;25(5):1247-60. doi: 10.1185/03007990902876271 .

PMID:
19344292
15.

Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands.

van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT.

Eur J Clin Pharmacol. 2008 Oct;64(10):1013-20. doi: 10.1007/s00228-008-0480-z. Epub 2008 Jul 10.

PMID:
18618103
16.

Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.

Contin M, Alberghini L, Candela C, Benini G, Riva R.

Epilepsy Res. 2016 May;122:79-83. doi: 10.1016/j.eplepsyres.2016.02.012. Epub 2016 Mar 2.

PMID:
26987080
17.

Generic substitution in the treatment of epilepsy: patient and physician perceptions.

Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ.

Epilepsy Behav. 2008 Nov;13(4):693-9. doi: 10.1016/j.yebeh.2008.06.001. Epub 2008 Sep 10.

PMID:
18589000
18.

Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population.

Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI.

Epilepsy Res. 2011 Jun;95(1-2):51-9. doi: 10.1016/j.eplepsyres.2011.02.012. Epub 2011 Mar 24.

PMID:
21435840
19.

Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.

Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS.

Neurology. 2008 Aug 12;71(7):525-30. doi: 10.1212/01.wnl.0000319958.37502.8e.

PMID:
18695164
20.

Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.

Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE.

Epilepsia. 2015 Sep;56(9):1415-24. doi: 10.1111/epi.13095. Epub 2015 Jul 23.

Supplemental Content

Support Center